To advance early science without diluting its core business, Gubra has launched Gubra Ventures. Zoë Johnson takes the helm of the new unit, aimed at expanding the pipeline with increased flexibility. #Gubra #LifeScience

Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

#Pfizer #obesity #weightloss #FosunPharma #YaoPharma #GLP1agonist #oralGIPanalogue #Metsera #EliLilly #NovoNordisk #Wegovy #ZealandPharma #metabolicdiseases #Roche #BoehringerIngelheim #GLP1glucagonagonist #StructureTherapeutics #AscletisPharma #WaveLifeSciences #Gubra
zurl.co/AwsrK

Goldman Sachs starts Gubra at “neutral,” cites balanced risk and limited upside Investing.com -- Goldman Sachs has initiated coverage on Gubra A/S with a “neutral” rating and a 12-month price target of Dkr520, representing a 23.9% upside from the current price of Dkr419.80, in a note dated Friday. The brokerage cited strong prospects for Gubra’s amylin asset GUBAmy and a promising early-stage pipeline but pointed to limited valuation upside relative to broader European biotech peers and what it described as a “balanced risk-reward profile.” Gubra, a Danish biotechnology company, operates a profitable contract research organisation (CRO) business that supports its pipeline focused on obesity. The CRO segment, Goldman noted, provides a differentiated revenue stream and has grown steadily with above-sector margins since the company’s IPO. The brokerage highlights how the CRO’s capabilities support Gubra’s development efforts, which include a number of obesity-targeted assets with varied mechanisms of action. The research identifies GUBAmy, an amylin analogue, as the central driver of the company’s future growth potential. Goldman Sachs estimates a potential peak sales opportunity of $5 billion for GUBAmy and flags its potential to serve as a meaningful therapy for patients unable to tolerate GLP-1 treatments. Analysts noted the asset’s strong positioning, supported by its partnership with AbbVie (NYSE:ABBV), which helps mitigate commercialization risk. The compound also competes with established therapies such as those from Novo Nordisk (NYSE:NVO), Zealand Pharma (NASDAQ:ZEAL) and Eli Lilly (NYSE:LLY). Despite the positive aspects of Gubra’s development strategy, Goldman Sachs said the stock’s current valuation leaves limited near-term upside. The brokerage places Gubra in the context of the wider European biotech landscape, where the upside potential is seen as less compelling when compared to its peers.

Click Subscribe #GoldmanSachs #Gubra #Biotech #Investing #StockMarket

AbbVie Enters Obesity Market with $2.2B Licensing Deal with Gubra

Video: youtube.com/shorts/Q0Nqv...

#ABBV #ABBVStock #ABBVNews #ABBVStockNews #AbbVie #AbbVieStock #AbbVieNews #AbbVieStockNews #AbbVieGubra #AbbVieWeightLoss #AbbVieObesity #Gubra

Nowa terapia na otyłość? AbbVie stawia na analog amyliny | Alert Medyczny AbbVie inwestuje miliardy w leczenie otyłości. Nowa terapia oparta na analogu amyliny może zmienić standardy terapii. Sprawdź szczegóły.

💊 AbbVie wkracza na rynek terapii otyłości. Firma podpisała umowę z Gubra na rozwój analogu amyliny GUB014295.

📌 Szczegóły: alertmedyczny.pl/nowa-terapia...

#Farmacja #Otyłość #AbbVie #Gubra

AbbVie and Gubra Collaborate to Develop Amylin Analog Targeting Obesity Treatment AbbVie and Gubra have partnered to advance GUB014295, an innovative amylin analog for obesity management, fostering potential growth and collaboration against global health challenges.

AbbVie and Gubra Collaborate to Develop Amylin Analog Targeting Obesity Treatment #United_States #AbbVie #North_Chicago #Gubra #GUB014295